Intratumoral microbial heterogeneity affected tumor immune microenvironment and determined clinical outcome of HBV-related HCC
Shengnan Li(Tianjin Medical University Cancer Institute and Hospital), Wei Lü(Tianjin Medical University Cancer Institute and Hospital), Hongcheng Lv(Tianjin Medical University Cancer Institute and Hospital), Yingnan Ye(Sun Yat-sen University), Tianqiang Song(Tianjin Medical University Cancer Institute and Hospital), Xiehua Zhang(Tianjin Medical University Cancer Institute and Hospital), Xiaofen Yue(Tianjin Medical University Cancer Institute and Hospital), Qian Li(Beijing Wuzi University), Liang Xu, Zeyu Wang(Anhui University), Jia Li(Kaiser Permanente), Han Xia, Shu Fan, Qiaoling Zhang(Inner Mongolia Agricultural University), Jiayu Lv(Beijing Academy of Agricultural and Forestry Sciences), Ningning Zhang(Chongqing University), Jinpu Yu(Tianjin Medical University Cancer Institute and Hospital)
Cited by 71
Related Papers
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
|The Lancet Oncology|2015|1.1k
Glioma targeted therapy: insight into future of molecular approaches
|Molecular Cancer|2022|727
Epithelial Injury Induces Keratocyte Apoptosis: Hypothesized Role for the Interleukin-1 System in the Modulation of Corneal Tissue Organization and Wound Healing
|Experimental Eye Research|1996|592
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
|Journal of Experimental & Clinical Cancer Research|2021|535
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
|Journal of Hematology & Oncology|2022|273